We are live on ! Find out more
ASMB icon

Assembly Biosciences

106 hedge funds and large institutions have $286M invested in Assembly Biosciences in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 42 increasing their positions, 20 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

45,071% more call options, than puts

Call options by funds: $7.68M | Put options by funds: $17K

110% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 20

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

3% more funds holding

Funds holding: 103106 (+3)

0.33% less ownership

Funds ownership: 7.21%6.88% (-0.33%)

34% less capital invested

Capital invested by funds: $435M → $286M (-$149M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
106
Holders Change
+3
Holders Change %
+2.91%
% of All Funds
2.3%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
29
Increased
42
Reduced
20
Closed
24
Calls
$7.68M
Puts
$17K
Net Calls
+$7.66M
Net Calls Change
+$4.55M
Name Holding Trade Value Shares
Change
Change in
Stake
Jennison Associates
1
Jennison Associates
New York
$34.5M +$1.31M +6,880 +3%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$30.4M -$434K -2,282 -1%
AC
3
Armistice Capital
New York
$27M +$13.8M +72,667 +77%
BlackRock
4
BlackRock
New York
$23.9M +$528K +2,778 +2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$16.6M +$2.32M +12,204 +14%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$12.9M +$59.5K +313 +0.4%
SAM
7
Sectoral Asset Management
Quebec, Canada
$11.4M +$2.09M +10,991 +18%
BBA
8
Baker Bros. Advisors
New York
$10.8M +$10.4M +54,555 +441%
RSCM
9
Rock Springs Capital Management
Maryland
$7.55M +$1.74M +9,167 +24%
O
10
OrbiMed
New York
$7.06M -$7.48M -39,377 -47%
EA
11
Emerald Advisers
Pennsylvania
$6.24M -$94.5K -497 -1%
Citadel Advisors
12
Citadel Advisors
Florida
$6.08M +$3.63M +19,080 +103%
State Street
13
State Street
Massachusetts
$6.03M -$5.84M -30,707 -45%
EMFAT
14
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.64M
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$4.22M +$1.79M +9,415 +57%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$3.89M +$519K +2,730 +13%
Northern Trust
17
Northern Trust
Illinois
$3.8M -$150K -790 -3%
N
18
Nuveen
North Carolina
$3.68M +$4.32M +22,739 New
Axa
19
Axa
France
$3.52M +$76.4K +402 +2%
JP Morgan Chase
20
JP Morgan Chase
New York
$3.06M +$279K +1,470 +9%
Millennium Management
21
Millennium Management
New York
$2.86M +$2.86M +15,030 +575%
Morgan Stanley
22
Morgan Stanley
New York
$2.83M +$1.43M +7,507 +75%
OAM
23
Oxford Asset Management
United Kingdom
$2.83M +$3.32M +17,461 New
Deutsche Bank
24
Deutsche Bank
Germany
$2.81M +$2.21M +11,604 +200%
VFA
25
Valeo Financial Advisors
Indiana
$2.71M

ASMB Hedge Fund Activity: Q2 2019 in Review

106 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2019, worth a combined $286M — down 34% from $435M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ASMB positions and 24 closed out — a net gain of 5 holders — while 42 added to existing stakes and 20 trimmed.

The largest buyer was Armistice Capital, adding an estimated $13.8M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $18.3M sold.

  • 106 institutional investors held Assembly Biosciences (ASMB) as of Q2 2019, up from 103 in Q1 2019.
  • Funds reported $286M of Assembly Biosciences stock for Q2 2019, down 34% quarter-over-quarter.
  • 29 funds opened new Assembly Biosciences positions in Q2 2019 and 24 closed out, a net change of +5 holders.
  • The largest Assembly Biosciences buyer in Q2 2019 was Armistice Capital, an estimated $13.8M added.
  • The largest Assembly Biosciences seller in Q2 2019 was EcoR1 Capital, an estimated $18.3M sold.

Based on aggregated 13F filings for Q2 2019.